Francesco Saccà, MD, PhD, University of Naples Federico II, Naples, Italy, provides recommendations on the management of myasthenic crisis in myasthenia gravis. Myasthenic crisis is usually managed with intravenous immunoglobulin (IVIg) or plasma exchange (PLEX), depending on what is more available and the patient’s comorbidities. Many patients have been treated successfully with anti-FcRns and complement inhibitors, but these treatments are too new for these to be recommended in guidelines as first-line treatments for myasthenic crisis. Dr Sacca recommends, based on real-world reports, that patients who don’t respond to either IVIg or PLEX should be immediately treated with anti-FcRns or complement inhibitors, rather than after having tried both treatments. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
